Vor Biopharma Inc.
VOR
$34.02
-$1.67-4.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.40M | 6.59M | 5.96M | 6.70M | 7.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 243.55M | 33.29M | 31.31M | 28.51M | 29.04M |
| Operating Income | -243.55M | -33.29M | -31.31M | -28.51M | -29.04M |
| Income Before Tax | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.57B | -32.49M | -30.71M | -27.56M | -27.84M |
| EBIT | -243.55M | -33.29M | -31.31M | -28.51M | -29.04M |
| EBITDA | -241.51M | -32.47M | -30.45M | -27.66M | -28.17M |
| EPS Basic | -251.24 | -5.21 | -8.77 | -8.05 | -8.15 |
| Normalized Basic EPS | -153.96 | -3.25 | -5.48 | -5.03 | -5.10 |
| EPS Diluted | -251.24 | -5.21 | -8.77 | -8.05 | -8.15 |
| Normalized Diluted EPS | -153.96 | -3.25 | -5.48 | -5.03 | -5.10 |
| Average Basic Shares Outstanding | 6.26M | 6.24M | 3.50M | 3.42M | 3.42M |
| Average Diluted Shares Outstanding | 6.26M | 6.24M | 3.50M | 3.42M | 3.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |